Introduction {#Sec1}
============

The APPROACH (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History) study was a double-blind randomized clinical trial comparing the effects of rosiglitazone with glipizide on the progression of coronary atherosclerosis \[[@CR1], [@CR2]\]. Patients with Type 2 diabetes mellitus (T2DM) are at increased risk for restenosis after intracoronary stent placement \[[@CR3]--[@CR6]\]. Moreover, prior studies have suggested that thiazolidinediones, which improve insulin sensitivity and have effects on vascular smooth muscle cell proliferation and neointimal hyperplasia, may reduce rates of in-stent restenosis in patients irrespective of their diabetic status \[[@CR7]--[@CR15]\].

The objectives of this pre-specified APPROACH sub-study were: (1) to determine the effect of rosiglitazone and glipizide on intra-stent neointima hyperplasia in patients with T2DM and coronary artery disease (CAD); (2) to determine the restenosis parameters measured by intravascular ultrasound (plaque behind stent, intra-stent intima hyperplasia volume); and (3) to report the quantitative coronary angiography (QCA) intra-stent late loss, intra-stent diameter stenosis \[DS\], and binary angiographic restenosis.

Materials and methods {#Sec2}
=====================

Study design and eligibility criteria {#Sec3}
-------------------------------------

A detailed description of the APPROACH trial has been previously published \[[@CR1]\]. In brief, the APPROACH study was a prospective multicenter, double-blind, randomized, active-controlled trial (Fig. [1](#Fig1){ref-type="fig"}) of 672 patients from 92 centers in 19 countries, who were aged 30--80 years with established T2DM and who had clinically indicated coronary angiography or percutaneous coronary intervention (PCI) between February 2005 and January 2007. Patients were included if they had at least one atherosclerotic plaque with \>50% luminal narrowing in a coronary artery, and if their diabetes was treated with either lifestyle approaches alone (with an HbA1C \> 7 and ≤10%), or with oral agents comprising 1 oral agent at any dose, or 2 oral agents where each was prescribed at ≤50% of its maximal dose (with an HbA1C \> 6.5 and ≤8.5%). Exclusion criteria were: ST-segment elevation myocardial infarction in the prior 30 days; coronary artery bypass graft surgery; severe valvular heart disease; left ventricular ejection fraction \<40%; any heart failure (New York Heart Association class I--IV); uncontrolled hypertension (systolic blood pressure \>170 mmHg or diastolic blood pressure \>100 mmHg); renal insufficiency (serum creatinine ≥1.5 mg/dl for men or ≥1.4 mg/dl for women); and active liver disease. Participant safety was monitored by an Independent Data Monitoring. Data analysis was performed according to a pre-specified plan that was developed with the approval of the steering committee.Fig. 1Patient disposition. *CVD* cardiovascular disease, *GLP* glipizide, *IVUS* intravascular ultrasound, *PCI* percutaneous coronary intervention, *RSG* rosiglitazone, *T2DM* type 2 diabetes mellitus

In this pre-specified analysis, all patients who underwent stent placement during APPROACH and had available serial IVUS or QCA measurements were included.

Quantitative angiography analysis {#Sec4}
---------------------------------

The angiograms were stored in DICOM format and analyzed offline by Core laboratory personnel (Cardialysis, Rotterdam, The Netherlands), using the CASS II analysis system (Pie Medical BV, Maastricht, The Netherlands). The following quantitative coronary angiography (QCA) analysis parameters were measured: computed-defined minimal luminal diameter (MLD) and reference vessel diameter (RVD) obtained by an interpolate method.

### Quantitative coronary angiography endpoints {#Sec5}

*Late loss* was defined as the difference in minimum lumen diameter between baseline and follow-up.

*Percent diameter stenosis* was defined as the minimum lumen diameter divided by the reference vessel diameter at the site of the MLD × 100.

*Binary angiographic restenosis* was defined as follow-up stenosis \>50%. This is reported as frequency and percentage.

Management of glycemia and follow-up {#Sec6}
------------------------------------

Patients were randomized in a 1:1 ratio to receive masked rosiglitazone (4 mg/day) or glipizide (5 mg/day) in one pill. After 2 and 3 months, the dose of masked study drug was increased if tolerated and if the mean daily glucose level calculated from the patient's logbook of capillary tests in the 3 days prior to the visit was ≥126 mg/dl (7.0 mmol/l). If more than 1 titration was required, 2 pills per day were given. Open-label metformin (maximal total daily dose 2,550 mg) and then once-daily basal insulin, or both was added after the first 3 months if needed to maintain a HbA1c ≤ 7% using a glycemic titration algorithm designed to provide comparable glycemic control between treatment groups. Non-study drugs were reduced before study drugs in the event of hypoglycemia requiring dose reductions. Unless informed consent was formally withdrawn, all patients were followed until 18 months from randomization and clinical status ascertained regardless of whether they continued to take study medication.

Intravascular ultrasound examination and image analysis {#Sec7}
-------------------------------------------------------

Following stent implantation IVUS was performed. After intracoronary administration of nitroglycerin, an ultrasound catheter (2.5F Atlantis SR Pro Imaging 40 MHz) connected to a Galaxy G2 digital imaging console (Boston Scientific, Natick, MA) was advanced into the target vessel. The imaging transducer was positioned just distal to an identifiable side branch, and then motorized pullback of the transducer was performed at 0.5 mm/s. If a participant required cardiac catheterization for a clinical indication between 9 and 18 months, follow-up IVUS examination could be performed at that time instead of at study completion.

Intravascular ultrasound outcomes {#Sec8}
---------------------------------

Core laboratory personnel (Cardialysis, Rotterdam, The Netherlands) who were blinded to treatment assignment analyzed all IVUS images using validated software (Curad, version 3.1, Wijk bij Duurstede, The Netherlands), that facilitates detection of luminal and external elastic membrane (EEM---also called vessel contour) boundaries in reconstructed longitudinal planes. In order to obtain a smooth appearance of the vessel wall structures in the longitudinal views, the Intelligate™ image-based gating method was applied \[[@CR16], [@CR17]\].

### Intravascular ultrasound endpoints {#Sec9}

*Plaque behind stent* was derived by subtracting the mean stent area from the vessel mean area.

*Percentage volume of intimal hyperplasia (%vol IH)* was defined as IH volume divided by stent volume.

Statistical methods {#Sec10}
-------------------

For baseline characteristics, continuous variables are expressed as mean and standard deviation, or median and interquartile range if non-normally distributed, with categorical variables reported as percentage. For continuous variables *P* values were based on Wilcoxon test, while for categorical variables *P* values were based on Fisher's exact test. The *P* values for treatment difference of continuous IVUS and QCA variables were based on analysis of covariance model (ANCOVA) with terms for treatment, baseline measurement, region, gender, cardiac procedure, and prior OAD medication. Two sample test was used for group comparisons at baseline and follow-up. For binary angiographic restenosis, Fisher's exact test was used.

Results {#Sec11}
=======

Participants {#Sec12}
------------

In total 672 (68% men) of mean (SD) age 61 (9) years, median diabetes duration of 4.8 years and mean haemoglobin HbA1C of 7.2 (0.9) % were randomized to either glipizide (*N* = 339) or rosiglitazone (*N* = 333) from 92 sites in 19 countries (Fig. [1](#Fig1){ref-type="fig"}). At the end of the study, 462 randomized patients had evaluable baseline and follow-up IVUS examinations. 173 had evaluable angiographic data and 113 had serial IVUS data from a vessel with PCI at baseline.

Patients were followed for a median of 18.6 months (IQR 18.2--18.9) and a mean (SD) of 16 (6) months; patients allocated to glipizide were adherent at 90.7% of visits and those allocated to rosiglitazone were adherent at 92.7% of visits.

In this analysis, 231 patients who underwent stent placement during the study and had available serial IVUS or QCA measurements were included. Patients who underwent stent placement do not represent randomized groups, however the distribution of these patients was similar between the randomized groups (glipizide *N* = 118, rosiglitazone *N* = 113).

Baseline characteristics were generally similar between the groups. (Table [1](#Tab1){ref-type="table"}). Patients in the rosiglitazone group had slightly higher serum creatinine, compared with glipizide (*P* = 0.01).Table 1Baseline characteristics of intervened patientsGlipizide (*N* = 118)Rosiglitazone (*N* = 113)P value*Demographic characteristics*Age, mean (SD), years60.4 (9.1)62.4 (8.1)0.14Male, *n* (%)84 (71.2%)92 (81.4%)0.09Weight, mean (SD), kg81.9 (17.5)80.2 (17.3)0.56BMI, mean (SD), kg/m^2^29.2 (4.9)28.7 (5.3)0.30Duration of diabetes, median \[IQR\], years4.5 \[1.5--9.5\]4.5 \[1.9--8.7\]0.77Hypertension, *n* (%)91 (77.1%)88 (77.9%)1.00Dyslipidemia, *n* (%)72 (61.0%)74 (65.5%)0.50Prior myocardial infarction, *n* (%)38 (32.2%)28 (24.8%)0.24Presenting condition, *n* (%) Acute coronary syndrome60 (50.9%)55 (48.7%)0.79 Elective procedure58 (49.2%)58 (51.3%)Baseline procedure, *n* (%) Coronary angiography6 (5.1%)6 (5.3%)1.00 Percutaneous coronary intervention112 (94.9%)107 (94.7%)Current smoker, *n* (%)20 (17.0%)24 (21.2%)0.50ACC/AHA lesion type, *n* (%) A14 (11.7)14 (12.1)0.53 B149 (41.5)48 (42.6) B235 (29.7)32 (28.3) C20 (17.1)19 (17.0)*Prior medication use*Aspirin106 (89.8%)102 (90.3%)1.00Other anti-platelet109 (92.4%)108 (95.6%)0.41Beta-blocker88 (74.6%)86 (76.1%)0.88ACE inhibitor or ARB80 (67.8%)71 (62.8%)0.49Nitrates57 (48.3%)56 (49.6%)0.90Statin97 (82.2%)94 (83.2%)0.86Fibrate or other lipid-lowering agent7 (5.93%)10 (8.9%)0.46*Vital signs and laboratory values*Blood pressure, mean (SD), mmHg Systolic129.9 (15.5)126.6 (15.5)0.17 Diastolic74.5 (9.5)73.2 (10.3)0.41HbA1c, mean (SD), %7.1 (0.8)7.0 (0.7)0.14Serum creatinine, mean (SD), µmol/L85.2 (19.5)93.7 (26.0)0.01BNP, median \[IQR\], pg/mL30 \[14--68\]25 \[12--58\]0.50Fasting insulin, median \[IQR\], µU/mL12.1 \[8.6--19.0\]13.0 \[8.6--18.1\]0.96LDL cholesterol, mean (SD), mg/dL87.6 (38.0)85.5 (36.6)0.66HDL cholesterol, mean (SD), mg/dL41.2 (10.5)40.9 (9.9)0.79Triglycerides, median \[IQR\], mg/dL154.0 \[113.7--200.9\]161.1 \[123.9--192.0\]0.61hsCRP, median \[IQR\], mg/L5.1 \[2.4--11.7\]6.1 \[3.7--13.3\]0.19MMP-9, median \[IQR\], µg/L102.1 \[48.1--202.4\]73.2 \[38.4--159.9\]0.38

All the DES implanted were from 1st DES generation. No difference in stent size were found between groups (Table [2](#Tab2){ref-type="table"}).Table 2Stent size distribution in the groupsBare metal stentDrug-eluting stentGlipizide *N* = 21Rosiglitazone *N* = 21*P* valueGlipizide *N* = 40Rosiglitazone *N* = 31*P* valueDiameter2.79 ± 0.603.05 ± 0.830.1262.58 ± 0.712.68 ± 0.540.592Length18.00 ± 7.2017.25 ± 5.100.83321.45 ± 7.8119.58 ± 7.020.257In this post-hoc analysis, neither rosiglitazone nor glipizide are randomized groups

Effect on intravascular ultrasound endpoints {#Sec13}
--------------------------------------------

There was no significant difference in the size of plaque behind stent between the rosiglitazone and glipizide groups at 18 months among those treated with a bare metal stent (−5.6 mm^3^ vs. 1.9 mm^3^; *P* = 0.61) or with a drug-eluting stent (12.1 mm^3^ vs. 5.5 mm^3^; *P* = 0.09) (Table [3](#Tab3){ref-type="table"}). Similarly, there was no significant difference in percentage intimal hyperplasia volume between the rosiglitazone and glipizide groups at 18 months among those treated with a bare metal stent (24.1% vs. 19.8%; *P* = 0.38) or with a drug-eluting stent (9.8% vs. 8.3%; *P* = 0.57) (Table [3](#Tab3){ref-type="table"}).

Effect on QCA endpoints {#Sec14}
-----------------------

Intra-stent late loss did not differ between the rosiglitazone and glipizide groups among those with a bare metal stent (0.76 mm vs. 0.71 mm; *P* = 0.51) or a drug-eluting stent (0.37 vs. 0.25; *P* = 0.41) (Table [3](#Tab3){ref-type="table"}). There was no difference in intra-stent diameter stenosis between the rosiglitazone and glipizide groups among those with a bare metal stent (32.3% vs. 30.4%; *P* = 0.50) or a drug-eluting stent (22.1% vs. 17.9%; *P* = 0.28) (Table [3](#Tab3){ref-type="table"}). The percentage of patients with binary angiographic restenosis did not differ between the rosiglitazone and glipizide groups among those with a bare metal stent (22.9% vs. 10.8%; *P* = 0.21) or a drug-eluting stent (4.6% vs. 1.8%; *P* = 0.58) (Table [3](#Tab3){ref-type="table"}).

Safety {#Sec15}
------

As noted previously, the patients who underwent stent placement do not represent randomized groups, however, there were no significant differences in cardiovascular events between the rosiglitazone and glipizide groups, which occurred infrequently during the trial (Table [4](#Tab4){ref-type="table"}).Table 3Results of quantitative coronary angiographic analysisIVUS measurementBare metal stent*P* valueDrug-eluting stent*P* valueGlipizide *N* = 21Rosiglitazone *N* = 21Glipizide *N* = 40Rosiglitazone *N* = 31Mean (SD), mm^3^*Vessel volume*Baseline302.3 (161.4)245.1 (104.3)0.18278.6 (132.6)302.4 (110.1)0.42Follow-up302.3 (160.5)241.0 (110.0)0.16288.6 (141.9)317.3 (102.6)0.35Change from baseline0.0 (29.3)−4.1 (39.8)10.0 (23.0)14.9 (34.1)Model-adjusted change (SE)8.7 (16.6), *P* = 0.609.8 (16.3), *P* = 0.556.7 (13.9) *P* = 0.6214.0 (14.3), *P* = 0.33Treatment difference (95% CI)1.1 (−24.9,27.1)0.937.3 (−7.4, 22.0)0.32*Stent volume*Baseline147.4 (81.1)125.8 (53.1)0.31140.5 (64.4)152.9 (61.0)0.42Follow-up145.5 (78.7)127.3 (60.0)0.41145.0 (65.8)155.7 (53.4)0.47Change from baseline−1.9 (15.4)1.5 (16.4)4.5 (10.8)2.8 (17.3)Model-adjusted change (SE)−1.2 (7.9), *P* = 0.883.5 (7.6), *P* = 0.650.3 (6.7), *P* = 0.96−0.4 (6.9), *P* = 0.95Treatment difference (95% CI)4.7 (−7.3, 16.6)0.43−0.7 (−7.8, 6.4)0.84*Plaque behind stent*Baseline154.9 (83.3)119.3 (57.5)0.11138.1 (77.9)149.6 (59.7)0.50Follow-up156.8 (85.2)113.7 (54.4)0.06143.6 (83.6)161.7 (58.7)0.29Change from baseline1.9 (19.1)−5.6 (26.0)5.5 (16.9)12.1 (22.4)Model-adjusted change (SE)10.3 (10.5), *P* = 0.336.0 (10.6), *P* = 0.585.7 (9.4), *P* = 0.5414.3 (9.7), *P* = 0.15Treatment difference (95% CI)−4.3 (−21.2, 12.6)0.618.6 (−1.4, 18.5)0.09*%volume of IH\**Baseline−0.1 (0.2)−0.01 (0.1)0.25−0.3 (1.0)−0.3 (0.80)0.75Follow-up19.7 (11.1)24.1 (17.1)0.338.0 (8.7)9.6 (11.3)0.51Change from baseline19.8 (11.1)24.1 (17.1)8.3 (8.7)9.8 (11.3)Model-adjusted change (SE)19.1 (7.2), *P* = 0.0123.9 (7.17), *P* = 0.00219.7 (4.3), *P* \< 0.000121.0 (4.4), *P* \< 0.0001Treatment difference (95% CI)4.9 (−6.2, 15.9)0.381.3 (−3.2, 5.8)0.57QCA measurementBare metal stent*P* valueDrug-eluting stent*P* valueGlipizide *N* = 37Rosiglitazone *N* = 35Glipizide *N* = 57Rosiglitazone *N* = 44*In*-*stent late loss (mm)*Mean0.710.760.250.37SD0.3800.5720.3040.586Model --adjusted Mean at month 18 (SE)0.85 (0.151)0.93 (0.162)0.510.75 (0.177)0.82 (0.183)0.41*In*-*stent DS (%)*Mean30.432.317.922.1SD15181220Model-adjusted Mean at month 18 (SE)32.98 (5.32)35.92 (5.678)0.5032.57 (6.346)35.82 (6.53)0.28*RVD (mm)*Mean2.622.582.622.78SD0.510.470.420.44Model-adjusted Mean at month 18 (SE)2.51 (0.100)2.53 (0.108)0.762.61 (0.121)2.67 (0.125)0.32*MLD (mm)*Mean1.841.752.152.27SD0.590.560.460.45Model-adjusted Mean at month 18 (SE)1.68 (0.151)1.60 (0.162)0.501.78 (0.141)1.79 (0.146)0.86*Binary angiographic restenosis, n(%)*4 (10.81)8 (22.86)0.211 (1.75)2 (4.55)0.58In this post-hoc analysis, neither rosiglitazone nor glipizide are randomized groups; \**%vol IH* percentage volume of intimal hyperplasiaTable 4Adverse cardiovascular events occurring either on-therapy or post-therapyPatients with an event, *n* (%)Glipizide (*N* = 118) (%)Rosiglitazone (*N* = 113) (%)All-cause death3 (2.5)5 (4.4)Cardiovascular death1 (0.8)2 (1.8)Stroke0 (0.0)2 (1.8)Myocardial infarction2 (1.7)5 (4.4)Nonfatal MI1 (0.8)4 (3.5)Fatal MI1 (0.8)1 (0.9)Cardiovascular death, nonfatal stroke, or nonfatal MI2 (1.7)7 (6.2)Coronary revascularisation14 (11.9)15 (13.3)In this post-hoc analysis, neither rosiglitazone nor glipizide are randomized groups

In the rosiglitazone group, 5 cardiovascular events occurred within 5 days of the baseline cardiac catheterization and were classified as procedure-related. These events included one revascularization, two nonfatal myocardial infarctions, one nonfatal stroke and one cardiovascular death.

Discussion {#Sec16}
==========

This study demonstrates no additional advantage of using rosiglitazone over glipizide in Type 2 diabetic patients for the reduction of in-stent restenosis; however it did demonstrate that both drugs have comparable effect on neointimial growth up to 18-months after coronary stent implantation.

On face value these results appear to contrast with the majority of the previously conducted studies, which have all reported significant reductions in the rates of in-stent restenosis in patients treated with thiazolidinediones compared to controls \[[@CR7]--[@CR15]\]. However it must be appreciated that these previous studies have inherent limitations which include: small sample sizes; a single-center location; the lack of independent core lab analysis; short follow-up; and PCI performed using only BMS. The recent POPPS study by Takagi et al. \[[@CR7]\] is an exception in view of its multi-center recruitment, and use of an independent core lab; however patients were still only treated with BMS, and follow-up was reported at only 6-months. On the contrary, the current study has distinct advantages in addition to being the largest single assessment to date of in-stent restenosis in patients treated with thiazolidinediones. These additional advantages include medium term follow-up, the use of both bare and drug eluting stents, and IVUS/QCA analysis performed by an independent core lab.

In the recent POPPS study, the neointimal growth index (neointimal volume/stent volume ×100) at 6-months amongst patients who were received a BMS, and treatment with pioglitazone and controls was 31 and 40% respectively \[[@CR7]\]; similarly in the current study the respective values of this index at 18-months for rosiglitazone and glipizide were 24 and 19%, respectively. Whilst the results for rosiglitazone are perhaps expected, the change noted with glipizide although welcome is unexpected, and obviously warrants further investigation.

The significance of the different follow-up periods, which were between 6--9 months in the earlier studies and 18-months in the current study, cannot be overstated. Previous IVUS studies have clearly demonstrated that neointimal growth continues to progress up to 18-months after implantation of a BMS, before regressing \[[@CR18]\]. This key observation not only highlights the importance of documenting the point in time when IVUS measurements are made, and keeping this in mind when interpreting the IVUS findings; but also indicates the arduous nature of trying to compare results from the current study to previous studies. Nevertheless, in the present study the comparatively lower rates of neointimal growth seen at 18-months, reiterates a comparable effect of both rosiglitazone and glipizide.

In-stent restenosis remains one of the undesired consequences of PCI, and although the introduction of drug eluting stents in 2002 improved rates of restenosis, they have been unable to eliminate it \[[@CR19]\]. There is a widely held misconception that restenosis is a benign phenomenon; however it is associated with both morbidity and mortality. In simplistic terms, restenosis increases the requirement for a repeat PCI procedure, which in itself is not risk free. For example a mortality rate of 2.5% was observed in the Ontario registry in those patients having target vessel revascularisation within a month of their initial PCI procedure \[[@CR20]\]. In addition rates of MI related to restenosis have been reported to be between 2 and 19% \[[@CR21], [@CR22]\].

In view of this it is no surprise that there is a great desire to identify adjunctive agents which may help reduce in-stent restenosis. This problem is particularly pertinent in diabetic patients owing to the identification of diabetes as an independent predictor of in-stent restenosis \[[@CR3], [@CR4]\]. The mechanisms underlying this increased risk are poorly understood, however it is considered amongst others to be the result of a combination of the greater degree of the vascular inflammation, and endothelial dysfunction seen in diabetics \[[@CR23], [@CR24]\]. The risk of in-stent restenosis is further compounded in T2DM patients because insulin resistance can aggravate restenosis, through the direct growth-factor like effect of insulin on vascular smooth muscle and neointimal cells \[[@CR25]\].

Poor glycaemic control is also implicated in promoting restenosis \[[@CR26]\], however previous studies which have reported the benefit of thiazolidinediones in reducing restenosis have indicated that this benefit occurs independently of the drug's effect on glycaemic control \[[@CR7]\]. There are many potential mechanisms by which thiazolidinediones may reduce in-stent restenosis including: (a) the inhibition of smooth muscle cell migration and proliferation \[[@CR27], [@CR28]\]; (b) the increased apoptosis in vascular smooth muscle cells \[[@CR29]\]; (c) a beneficial effect on local inflammation \[[@CR30], [@CR31]\]; (d) an anti-thrombotic effect \[[@CR32]\]; and (e) a beneficial effect on fasting insulin levels, thereby preventing insulin driven atherosclerosis \[[@CR25], [@CR33]\].

In the end, it is important to highlight recent concerns associated with rosiglitazone use. Following drug launch, a metanalysis published in 2007 showed, indeed, an increased risk of myocardial infarction and cardiovascular death associated with rosiglitazone \[[@CR34]\]. The recent RECORD trial also demonstrated an increased risk of heart failure events in people treated with rosiglitazone \[[@CR35]\]. Eventually, the FDA mandated a study comparing rosiglitazone and pioglitazone with placebo, known as TIDE and then stopped the inclusion of the patients. Rosiglitazone has subsequently been removed from the EU market however it remains on available on the US market albeit with severe restrictions.

Limitations {#Sec17}
-----------

IVUS analyses were available in half of the patients included in the present study and could not be representative of overall population. Stent design was not pre-specified for the different groups.

Conclusions {#Sec18}
===========

This study indicates that both rosiglitazone and glipizide have a similar effect on neointimal growth at medium term follow-up, a finding that warrants investigation in dedicated randomized trials.
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